Genelabs Technologies, Inc. - Company Information

Scientific Advisory Board

		Home / Company Information / Scientific Advisory Board
		Scientific Advisory Board

Genelabs has assembled a multidisciplinary Scientific Advisory Board of distinguished scientists to provide guidance and insight for our drug discovery research programs. The following advisors have extensive expertise in chemistry, virology, molecular biology, microbiology and gene expression -- all areas of critical importance in Genelabs drug discovery process.

Charles Cantor, Ph.D.
Chief scientific officer of Sequenom, Inc.; Professor, Department of Biomedical Engineering and Biophysics; Director, Center for Advanced Biotechnology, Boston University; and member of the National Academy of Sciences

John Fried, Ph.D.
President, Fried and Company, Inc.; formerly Vice Chairman of the Board of Directors of Syntex Corporation and President of Syntex Research

Stanley M. Lemon, M.D.
Professor, Departments of Microbiology & Immunology and Internal Medicine at University of Texas Medical Branch

David A. Stevens, M.D.
Professor and Associate Chief of the Division of Infectious Diseases and Geographic Medicine at Stanford University

Richard J. Whitley, M.D.
Professor of Pediatrics, Microbiology and Medicine at the University of Alabama at Birmingham